AmgenvsBridgeBio Pharma

AMGN and BBIO stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$465.67

Value $251B

-0.30%
AMGN's page

BBIO

BridgeBio Pharma, Inc.

$78.30

Value $15.2B

+0.17%
BBIO's page

Amgen (AMGN) has a market value of $251B and BridgeBio Pharma (BBIO) $15.2B. Over the last year, with dividends, AMGN moved +42.3% and BBIO +18.2%. Dividend yield: AMGN 2.13%, BBIO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$251B

    BBIO$15.2B

    AMGN is 17 times BBIO

  • Revenue, 12 months

    AMGN$38.9B

    BBIO$946M

    AMGN is 41 times BBIO

  • Net income, 12 months

    AMGN$9.4B

    BBIO-$566M

  • Operating margin

    AMGN32.4%

    BBIO-38.5%

    70.9 points apart

  • ROIC

    AMGN16.2%

    BBIO-97.6%

    113.7 points apart

  • P/E

    AMGN26.7

    BBIO–

  • Dividend yield

    AMGN2.1%

    BBIO0.0%

    2.1 points apart

  • 5-year return

    AMGN+157.4%

    BBIO+63.5%

    93.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+157.4%

BBIO+63.5%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsBBIOWith dividends
1 year since November 12, 2025+42.3%Price +38.5%+18.2%Price +18.2%
3 years since November 13, 2023+91.0%+24.1% a yearPrice +74.6%+184.5%+41.7% a yearPrice +184.5%
5 years since November 12, 2021+157.4%+20.8% a yearPrice +120.3%+63.5%+10.3% a yearPrice +63.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenBBIOBridgeBio Pharma

Valuation

AMGNBBIO
Valuation
Price$465.67$78.30
Market value$251B$15.2B
Enterprise value (EV)$292B$16.3B
P/E26.7–
P/E, 5-year median23.0–
P/B17.5–
EV/EBIT23.1–
Free cash flow yield3.8%–

Results and growth

AMGNBBIO
Results and growth
Revenue, 12 months$38.9B$946M
Net income, 12 months$9.4B-$566M
Free cash flow, 12 months$9.6B-$370M
Earnings per share, 12 months$17.25-$3.03
Revenue growth, year on year10.0%126.3%
Revenue growth a year, past+7.6%over 5 years+127.4%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNBBIO
Margins and returns on capital
Gross margin70.9%94.3%
Operating margin32.4%-38.5%
Net margin24.1%-59.8%
ROIC16.2%-97.6%
ROE87.8%–

Balance sheet

AMGNBBIO
Balance sheet
Cash$13.2B$1.5B
Total debt$54.0B$2.6B
Net debt / EBITDA2.3–
Interest cover4.8×-7.1×

Dividends and buybacks

AMGNBBIO
Dividends and buybacks
Dividend yield2.1%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–0.3%
Shareholder yield2.1%0.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or BBIO

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or BridgeBio Pharma?

By market value, Amgen ($251B) is about 16.5 times BridgeBio Pharma ($15.2B), at today's prices.

How did AMGN and BBIO stock do over the last 5 years?

Since November 12, 2021, AMGN's price moved +120.3% and BBIO's +63.5%. With dividends: AMGN +157.4% (+20.8% a year), BBIO +63.5% (+10.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or BBIO?

The dividend yield at today's price is 2.13% for Amgen and none for BridgeBio Pharma. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or BridgeBio Pharma?

Over the last twelve months, the net margin was 24.1% for Amgen and -59.8% for BridgeBio Pharma, and the operating margin 32.4% and -38.5%. Revenue was $38.9B and $946M.

Which is the better investment, Amgen or BridgeBio Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.